Articles by Arnaud Deladeriere

1. Europe's ATMP Opportunity Still Requires Local Navigation 8/27/2026

   European nations offer a welcoming environment for clinical-phase cell and gene therapies. Don't assume the same flexibility carries through to commercialization.

2. The Unspoken Truth About Cell Therapy Product Understanding 8/27/2026

   Developers often discover important attributes after it's too late to act on them. A well-designed program asks what's needed for commercialization and works backward.

3. Let's Stop Treating Allogeneic Cell Therapy As One Thing 7/14/2026

   Industry is beginning to accept that allogeneic cell therapy spans categories, and success depends on aligning biology, regulation, and economics unique to each product.

4. Allogeneic Cell Therapy Is Still Learning What Biology Will Allow 7/14/2026

   Allogeneic cell therapy is advancing through smarter donor selection and manufacturing control, showing how biology, process design, and product consistency drive success.

5. How AI Could Clear Logistics Roadblocks Limiting Patient Access To CGT 4/23/2026

   Patient access often gets mischaracterized solely as a cost and pricing issue. A discussion among industry leaders reaches a deeper, more complex conclusion.

6. COGs And Biology, Two Endpoints Needlessly At Odds In Advanced Therapy 3/20/2026

   Problems emerge when development, manufacturing, and clinical priorities fail to converge in cell and gene therapy development.

7. The Real Reason We Haven't Fully Automated Cell Therapy Yet 2/26/2026

   Manual cell therapy workflows often set the tone for automation. This discussion suggests the approach is flawed and presents automation as a chance to innovate.

8. In Vivo's Biggest Threat — Comparison To Old Models 1/23/2026

   In vivo CAR-T is not simply ex vivo without a manufacturing step. It is a different modality that relies on biological systems to regulate outcomes.

9. CGT Industrialization Starts With CDMO Alignment 12/19/2025

   Fragmented processes are stalling progress. By aligning CDMOs through transparency and standards, developers can move past the COGS obsession and stabilize the supply chain.

10. AI Is Not The CMC Revolution You're Looking For, And That's OK 11/18/2025

    Advanced therapy development today is less about big funding, more about frugality. Artificial intelligence unlocks a competitive advantage.